Monotherapy is cost-effective and gives deliverable action directly to the site of action in a few minutes, and is said to be a safe and effective method for treating idiopathic pulmonary fibrosis (IPF). Over the coming years, rising cases of IPF will support the expansion of the market.
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/30070
High number of research & development projects, increasing investments, and favorable regulatory policies are some other factors supporting growth of the market for pulmonary fibrosis treatment. Majority of the population living with pulmonary fibrosis is being treated with traditional corticosteroid combination drugs with limited efficacy.